Therefore, the road towards the development of a consensus guideline on the BRCA1/2 testing should be fully covered quickly and facilitated through close cooperation between experts in the field of ovarian cancer specialists, pathologists, molecular biologists, and clinical-molecular geneticists. This evidence concerns the gene BRCA1 and ovarian carcinoma.